Page 76 - I. Chemical biology and drug discovery
P. 76
[I. Chemical biology and drug discovery-41]
Identification of a natural product inhibitor for Src-homology
phosphotyrosyl phosphatase 2
Jae Kwan Kim¹˙#, Sun-Young Yoon¹˙#, Sang J. Chung¹˙*
¹College of pharmacy, Sungkyunkwan University, Suwon 16419, South Korea
cardiovascular disease, neuropathy, kidney damage, and so on. There are two types of diabetes: type 1 diabetes
(T1D) and type 2 diabetes (T2D). Especially type 2 diabetes (T2D) is occurred by a disability of glucose uptake and
is mainly related to insulin resistance. Src-homology phosphotyrosyl phosphatase 2 (shp2) is one of the targets for
type 2 diabetes (T2D). It has been reported that overexpression of SHP2 causes various types of cancer: obesity and
diabetes. Therefore, the Inhibition of SHP2 activity can improve type 2 diabetes (T2D) by enhancing insulin sensitivity.
In order to identify a potential therapeutic compound for diabetes, 658 natural compounds were screened by
enzyme kinetics and selected by C2C12 cell viability test. SHP2 expression and purification proceeded for enzyme
kinetics and IC₅₀ and Ki were examined. Also, we confirmed whether SHP2 is a target for diabetes by performing
siRNA knockdown. These results implicate that JK102 could be a therapeutic target for diabetes.
